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Abstract
Introduction: The	gut	microbiota	is	involved	in	the	regulation	of	cognition,	mood,	anxi-
ety,	and	pain,	and	can	impact	cognitive	functions	by	producing	neuroactive	substances	
or releasing bacterial by- products and metabolites. No information is available on the 
effects	of	a	probiotic	supplementation	on	brain	function	of	HIV+	subjects.	In	light	of	
the	above	considerations,	we	performed	a	pilot	study	in	cART-	treated	HIV-	1-	positive	
patients	with	long-	term	virologic	suppression.	The	aims	were	to	analyze	the	effect	of	
high-	concentration	multistrain	probiotic	supplementation	(Vivomixx®;	Visbiome®)	on	
several neurocognitive abilities and to evaluate the safety of this supplementation.
Methods: To	 address	 those	 issues,	 neurocognitive	 performances	were	 explored	by	
administering	 neuropsychological	 tests;	moreover,	miRNA-	29a-	c	 levels	were	meas-
ured	in	cerebrospinal	fluid	(CSF)	to	confirm	the	persistent	undetectable	levels	of	HIV-	
RNA	in	the	central	nervous	system	after	probiotic	supplementation.
Results: Our	results	show	that	the	Rey	auditory	verbal	learning	test	(RAVLT)	(immedi-
ate	and	delayed	recall),	Rey-	Osterrieth	complex	figure	test	(ROCF)	(copy	immediate	
and	delayed	recall),	phonological	verbal	fluency	(PVF)	test,	Toronto	alexithymia	scale-
	20	(Tas-	20),	State-	trait	anxiety	inventory	Y-	2	(STAY	Y-	2),	and	time	and	weight	estima-
tion	test	(STEP)	scores	improved	significantly	during	the	study.	Moreover,	we	found	
unchanged	levels,	associated	to	high	degree	of	individual	variability,	in	miRNA-	29	lev-
els	in	CSF	collected	before	and	after	probiotic	supplementation.
Conclusions: In	conclusion,	we	observed	that	HIV	patients	treated	with	6	months	of	
this probiotic supplementation appear to have an improvement in some neurocogni-
tive	 functions;	moreover,	 this	 approach	 is	 safe	and	did	not	modify	 significantly	 the	
levels	of	miRNA	in	CSF.	Further	studies	are	needed	to	better	understand	the	contribu-
tion	of	the	probiotics	in	modulating	gut–brain-	axis	in	HIV	patients.
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1  | INTRODUCTION
Probiotic supplementation has become a common practice to control 
the	 dysbiosis	 associated	 to	 many	 chronic	 inflammatory	 conditions,	
such	as	inflammatory	bowel	diseases	(IBD)	with	positive	effects	on	the	
clinical	outcome	(Shen	et	al.,	2014).
HIV	is	a	chronic	inflammatory	disease	in	which	a	proinflammatory	
change	in	the	gut	microflora	associated	to	a	number	of	structural,	im-
munological,	and	functional	changes	are	present	(Ziberman-	Schapira	
et	al.,	2016).
Consequently,	the	administration	of	probiotics	to	HIV	patients	has	
a	rationale,	even	though	the	administration	of	live	bacteria	in	the	pres-
ence of a viral infection and associated immunosuppression could be 
a	risk	for	sepsis	and	abscesses	(Haghighat	&	Crum-	Cianflone,	2015).
Few studies have been published on the role of a probiotic sup-
plementation	 on	 SIV+	 monkeys	 and	 on	 HIV+	 humans,	 with	 prom-
ising results regarding the immune reconstitution of the gut barrier 
and	 immune	 response	 (Cunningham-	Rundles	 et	al.,	 2011;	 d’Ettorre,	
Ceccarelli,	Andreotti,	et	al.,	2015;	d’Ettorre,	Ceccarelli,	Giustini,	et	al.,	
2015;	Klatt	et	al.,	2013;	Klatt,	Funderburg,	&	Brenchley,	2013;	Ortiz	
et	al.,	2016;	Villar-	García	et	al.,	1999).	No	information	is	available	on	
the effects of a probiotic supplementation on brain function and be-
havior	of	HIV+	subjects.	The	gut	microbiota	 is	 involved	 in	 the	regu-
lation	 of	 cognition,	mood,	 anxiety	 and	 pain	 as	 previously	 shown	by	
studies	performed	in	germ-	free	animal	models	or	in	animals	exposed	
to pathogenic bacterial infections treated by antibiotic drugs or pro-
biotic	 supplementations	 (Cryan	&	Dinan,	 2012).	The	 gut	microbiota	
can	impact	mood	and	cognitive	functions	(Desbonnet,	Garrett,	Clarke,	
Bienenstock,	&	Dinan,	2008;	Desbonnet	et	al.,	2010)	in	different	ways,	
i.e.,	 by	 producing	 neuroactive	 substances	 or	 releasing	 bacterial	 by-	
products and metabolites.
In light of the above considerations and the fact that neurocogni-
tive	impairment	affects	more	than	50%	of	HIV-	1-	infected	individuals	
(Nightingale	et	al.,	2014),	we	performed	a	pilot	study	in	cART-	treated	
HIV-	1-	positive	patients	with	long-	term	virologic	suppression.	The	aims	
were	(1)	to	analyze	the	effect	of	high-	concentration	multistrain	probi-
otic	 (Vivomixx®	Visbiome®) supplementation on neuropsychological 
tests	exploring	several	neurocognitive	abilities	and	(2)	to	evaluate	the	
safety of this supplementation.
The primary endpoint aimed at evaluating the effect of this specific 
kind of probiotics supplementation on the following neuropsycholog-
ical	tests:	episodic	declarative	memory	(Rey	Auditory	Verbal	Learning	
Test	RAVLT),	visual	perception	and	long-	term	visual	memory	function	
(Rey-	Osterrieth	Complex	Figure,	ROCF),	executive	function	and	ver-
bal	 fluency	 (Frontal	Assessment	Battery,	 FAB;	Test	 of	Phonological/
Semantic	Verbal	Fluency,	PVF/SVF),	working	memory’s	number	stor-
age	capacity	and	short-	term	memory	(Back	and	Forward	Digit-	Verbal	
Span),	visuospatial	 short-	term	working	memory	 (Corsi	 block-	tapping	
test,	 CBTT),	 visual	 attention	 and	 task	 switching	 (Trail	 making	 test,	
TMT),	and	frontal	functions	(Time	and	weight	estimation	test,	STEP).
To	evaluate	the	safety	of	the	product	at	the	neurological	 level,	a	
lumbar puncture before and after the probiotic supplementation was 
performed. Due to the invasive procedure of the lumbar puncture and 
associated	 risks,	 a	 control	 group	 was	 excluded.	 CSF	 miRNA-	29a-	c	
levels	were	 evaluated.	miRNAs	 are	 short	 single-	stranded	noncoding	
RNAs	 that	have	been	 shown	 to	play	a	 role	 in	modulating	HIV-	1	 in-
fection,	either	directly	or	 indirectly	 (Monteleone	et	al.,	2015;	Müller	
et	al.,	2016;	Su,	Aloi,	&	Garden,	2016;	Swaminathan,	Navas-	Martín,	&	
Martín-	García,	2014).
2  | MATERIALS AND METHODS
2.1 | Study design, recruitment, and study eligibility 
criteria
This	is	a	longitudinal,	nonrandomized	designed,	single-	arm,	pilot	study	
(Figure	1)	 registered	on	 the	ClinicalTrials.gov	 registry	with	 identifier	
number	NCT02276326.	The	inclusion	criteria	allowed	to	enroll	HIV-	
positive	patients	(1)	who	had	signed	the	informed	consent,	(2)	women	
or	men	at	least	18	years	of	age,	(3)	in	HAART	with	HIV-	RNA	<50	cop-
ies/ml,	 and	 CD4	 counts	 >400	cells/mm3.	 Exclusion	 criteria	 were:	 
(1)	 patients	 with	 known	 allergy	 or	 intolerance	 to	 the	 product,	 
(2)	diarrhea,	(3)	history	of	or	current	inflammatory	diseases	of	the	small	
or	large	intestine,	(4)	any	past	or	current	systemic	malignancy,	(5)	previ-
ous	or	actual	drug	addiction,	(6)	use	of	antibiotics	or	probiotics	during	
the	3	weeks	prior	the	enrollment,	(7)	previous	or	actual	psychiatric	dis-
orders,	(8)	previous	or	actual	neurological	disorders,	and	(9)	pregnancy.
Ten	HIV-	1-	positive	 patients	 successfully	 treated	with	ART	were	
recruited	at	the	Division	of	Infectious	Diseases,	Department	of	Public	
Health	and	 Infectious	Diseases,	Hospital	of	 “Sapienza”	University	of	
Rome	(Italy)	from	May	2014	to	February	2015.
All	HIV-	1-	infected	patients	underwent	neuropsychological	test-
ing	 and	 lumbar	 puncture	 before	 (T0)	 and	 after	 (T6)	 probiotic	 sup-
plementation	of	cART,	 in	 this	way,	each	patient	was	 the	control	of	
oneself.	(Figure	1).	Because	lumbar	puncture	is	considered	a	proce-
dure with several risks and in literature there is no reported study 
where	 lumbar	 puncture	 was	 performed	 in	 the	 control	 arm,	 our	
Institution considered it unethical to have a control group undergo-
ing such a procedure.
Patients	received	a	high-	concentration	lyophilized	multistrain	pro-
biotic	supplement	twice	a	day	for	6	months	(1.8	×	1012	live	bacteria/
day	of	a	mix	of:	Lactobacillus plantarum	DSM	24730,	Streptococcus ther-
mophilus	DSM	24731,	Bifidobacterium breve	DSM	24732,	Lactobacillus 
paracasei	DSM	24733,	Lactobacillus delbrueckii subsp. bulgaricus	DSM	
24734,	Lactobacillus acidophilus	DSM	24735,	Bifidobacterium longum 
DSM	24736,	 and	Bifidobacterium infantis	 DSM	 24737)	 produced	 at	
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Danisco	 Dupont,	WI,	 USA	 and	 currently	 sold	 in	 Europe	 under	 the	
brand	Vivomixx®	and	in	the	USA	as	Visbiome®.
2.2 | Ethics statement
The researchers declare compliance with ethical practices upon sub-
mission of a manuscript and that clinical investigations were con-
ducted	 according	 to	 the	 principles	 expressed	 in	 the	Declaration	 of	
Helsinki.	The	study	was	approved	after	amendment	(no	control	group	
and lumbar puncture to the untreated subjects) by the institutional 
review	board	(Department	of	Public	Health	and	Infectious	Diseases,	
“Sapienza”	University	of	Rome	and	the	Ethics	Committee	of	Umberto	
I	 General	Hospital,	 Rome)	 on	 16th	 January	 2014.	 All	 study	 partici-
pants gave written informed consent. The authors declare that the 
Department of Public Health and Infectious Disease where patients 
were recruited is fully equipped for the planned interventions. The 
authors confirm that all ongoing and related trials for this drug/inter-
vention are registered.
2.3 | Cerebrospinal fluid measurements
CSF	was	collected	by	lumbar	puncture,	centrifuged,	and	cell-	free	su-
pernatant	samples	stored	in	aliquots	at	−70°C	until	analysis	of	miRNA-	
29a/b/c	species.
2.4 | Neuropsychological test battery
All	 patients	 underwent	 an	 accurate	 neuropsychological	 assessment	
through	a	complete	neuropsychological	test	battery	(Lezak,	Howieson,	
&	Loring,	2014).	The	preliminary	cognitive	evaluation	was	based	on	the	
administration	of	Mini-	Mental	State	Examination	(Folstein,	Folstein,	&	
McHugh,	1975)	 (MMSE,	score:	0–30)	followed	by	a	specific	battery	
of	 tests	 to	 explore	 the	main	 cognitive	domains	 (memory,	 attention,	
executive	function,	and	language)	(Belleville,	Rouleau,	&	Caza,	1998;	
Sannio	 Fancello,	 Vio,	 &	 Cianchetti,	 2006)	 by	 means	 of	 ROCF	 Test	
(Meyers	&	Meyers,	1995;	Rey,	1958)	(copy	immediate	and	copy	de-
layed	recall,	scores,	respectively,	0–35	and	0–36),	RAVLT	(immediate,	
delayed	recall	and	recognition;	scores,	respectively:	0–75,	0–15	and	
0%–100%),	Verbal	Span	(Digit	Forward	and	Digit	Back),	FAB	(score:	
0–18),	CBTT	(Kessels,	van	Zandvoort,	Postma,	Kappelle,	&	de	Haan,	
2000)	(Forward	and	Backward),	Visual	Search	Test	(Attention	Matrices	
Test)	Trail	Making	Test	(Reitan,	1992)	(TMTA:	mean	value	29,	insuf-
ficient	score	>78	and	TMTB:	mean	value	75,	insufficient	score	>273),	
Test	of	Weights	and	Measures	Estimation	(Nichelli	et	al.,	2002)	(STEP:	
Time:	 score	 0–36,	 normal	 value	 18;	 Weight:	 score	 0–36,	 normal	
value	18;	Total:	score	0–72,	normal	value	36),	Test	of	Phonological/
Semantic	Verbal	Fluency	(PVF	and	SVF),	Raven’s	Colored	Progressive	
Matrices	(CPM47:	nonverbal	intelligence),	and	Aachener	Aphasia	Test	
(AAT	scores:	0–29	aphasia;	>29:	normal;	<17	serious	aphasia).	At	the	
same	 time,	 to	 assess	 psychological	 manifestations	 (alexithymia,	 de-
pression,	state	and	trait	anxiety),	all	patients	were	evaluated	through	
a	 set	 of	 questionnaires:	 Toronto	Alexithymia	 Scale-	20	 (Bressi	 et	al.,	
1996)	 (Tas-	20	 score	≤51:	non-	alexithymia,	 ≥61:	 alexithymia.	 Scores	
from	52	to	60:	possible	alexithymia),	Beck	Depression	Scale	II	(Storch,	
Roberti,	&	Roth,	2004)	(BDI-	II,	score:	0–63,	persistent	values	around	
17	suggest	need	of	treatment),	and	State-	Trait	Anxiety	Inventory	Y-	1	
and	Y-	2	 (Spinnler	&	Tognoni,	1987)	 (STAY	Y-	1,	Y-	2	scores:	20–80).	
Where	necessary	the	scores	were	adjusted	for	age,	sex	and	instruc-
tion levels as required to the normative standards based on the rela-
tive	Italian	validation	manuals	(Barletta-	Rodolfi,	Gasparini,	&	Ghidoni,	
2011).	All	the	tests	with	the	relative	validation	chosen	for	our	battery,	
are	 part	 of	 the	 “category	 A”	 according	 to	 Bianchi	 criteria.	 (Bianchi,	
F IGURE  1 The	CONSORT	flow	diagram	
of	the	clinical	trial.	Experimental	design	of	
the study
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2008).	The	tests	used	are	standard	normalized	tests	for	which	normal	
subject performances are known.
2.5 | TaqMan- based real- time RT- PCR technique 
for microRNAs
MicroRNAs	were	quantified	by	real-	time	RT-	PCR	Taqman	assays	(hsa-	
miRNA-	29a,	 hsa-	miRNA-	29b,	 hsa-	miRNA-	29c,	 (Applied	 Biosystem,	
Monza,	Italy)	as	previously	described	(Monteleone	et	al.,	2015).	Briefly,	
miRNAs	were	extracted	from	CSF	using	the	Total	RNA	Purification	Kit	
(Norgen,	Thorold,	Canada).	Then,	miRNAs	were	reverse-	transcripted	
using	 a	 TaqMan	MicroRNA	Reverse	 Transcription	Kit,	 according	 to	
the	 manufacturer’s	 protocols	 (Applied	 Biosystems).	 Real-	time	 PCR	
was carried out in a final volume of 20 μl	using	a	LightCycler480	in-
strument	 (Roche,	 Basel,	 Switzerland).	 The	 constitutively	 expressed	
hsa-	miRNA-	16	and	hsa-mir-24	were	used	as	internal	controls	as	pre-
viously	reported.	Expression	values	of	miRNA-	29s	were	calculated	by	
the	comparative	threshold	cycle	(CT)	method.
2.6 | Bacterial DNA isolation from fecal samples
Bacterial	DNA	from	fecal	 samples	was	extracted	using	 the	QIAamp	
DNA	Stool	Mini	Kit	(Qiagen,	Hilden,	Germany).	Approximately	200	mg	
of	feces	were	cut	from	frozen	samples	using	sterile	disposable	scalpel,	
resuspended	 in	1.4	ml	of	ASL	 lysis	 buffer	 from	 the	 stool	 kit,	 added	
with	glass	beads	(150–212	μm	Sigma-	Aldrich,	USA),	and	homogenized	
thoroughly.	The	suspension	was	incubated	at	95°C	for	5	min	and	DNA	
was	purified	according	to	the	manufacturer’s	 instructions.	DNA	was	
eluted in 200 μl	of	AE	buffer	(provided	in	the	kit)	and	stored	at	−20°C.
2.7 | Statistical analysis
Statistical	analyses	were	done	using	SPSS	software,	version	20.00	(IBM,	
Somers,	NY,	USA).	Results	obtained	from	neuropsychological	assess-
ment	and	levels	of	miRNA-	29	before	(T0)	and	after	6	months	of	pro-
biotic	 (T6)	supplementation	were	evaluated	using	the	Wilcoxon	test.	
Differences	in	MiRNA-	29a-	c	expression	at	T0	and	T6	were	assessed	by	
the	Kruskal–Wallis	test.	The	correlations	between	MiRNA-	29a-	c	levels	
and	neurological	test	scores	were	evaluated	using	the	Pearson’s	test.	
Differences were considered statistically significant when p	<	.05.
3  | RESULTS
3.1 | Demographic and clinical characteristics of 
HIV- 1- positive patients
All	 subjects	 enrolled	 were	 HIV-	1-	infected	 Caucasian	 men	 with	 a	
median	 age	 of	 42	years	 (22–53	years).	 They	 initiated	 therapy	 dur-
ing	chronic	HIV-	1	 infection	and	had	been	on	cART	 for	a	median	of	
6	years	(IQR,	1.75–16.25	years).	Pretherapy	median	CD4+	cell	count	
was 255 cells/mm3	(IQR,	42.75–406.75	cells/mm3),	and	zenith	HIV-	1	
RNA	median	 value	was	5.0	log/ml	 (IQR,	 4.81–5.61	log/ml).	All	 sub-
jects	had	been	in	virologic	suppression	(<37	HIV-	1	RNA	copies/ml)	for	
at	least	1	year	and	their	median	CD4+	cell	count	was	674	(IQR,	564–
824	cells/mm3)	and	683	(IQR,	610–818	cells/mm3) cells/mm3,	respec-
tively,	before	and	after	probiotic	supplementation	of	cART.	HIV-	RNA	
and	a	search	for	neurotropic	viruses	were	negative	in	all	CSF	samples.	
As	reported	in	the	exclusion	criteria,	no	patients	enrolled	presented	
previous	or	actual	drug	addiction,	psychiatric	disorders	or	neurological	
diseases.	Average	education	level	was	12	years.
3.2 | Neuropsychological performance after 
probiotic supplementation
A	battery	 of	 neuropsychological	 tests	was	 administered	 to	 all	HIV-	1-	
positive	patients	before	(T0)	and	after	6	months	of	probiotic	supplemen-
tation	(T6).	The	tests	were	readministered	after	6	months	and	a	parallel	
form	was	used	 for	RAVLT	 (immediate	 and	delayed	 recall)	 the	parallel	
form,	according	to	the	Italian	validation.	 (Barletta-	Rodolfi	et	al.,	2011).	
None of the patients studied had received prior neurocognitive tests.
The results of neuropsychological tests are showed in Table 1. In 
particular,	we	observed	 a	 significant	 difference	between	T0	 and	T6	
for	immediate	and	delayed	recall	of	RAVLT	(immediate:	p = .0273; de-
layed: p	=	.0299),	immediate	and	delayed	recall	of	ROCF	(immediate:	
p	=	.0058;	delayed:	p	=	.0019).
Also,	PVF	(p	=	.0137),	STEP	(time:	p = .0246; weight: p	=	.022),	Tas-	
20	 (p	=	.0421),	 STAY	Y-	2	 (p	=	.0225),	 and	CBTT-	Forward	 (p = .0322) 
test	scores	increased	significantly	in	HIV-	1-	positive	patients	who	took	
probiotics twice a day for 6 months.
By	contrast,	 no	 significant	differences	were	observed	 for	 the	other	
neuropsychological	test	scores	examined	before	and	after	probiotic	intake.
3.3 | Expression of microRNA- 29a- c
The	 analysis	 of	 miRNA-	29a-	c	 levels	 in	 CSF	 collected	 from	 HIV-	1-	
infected	patients	before	(T0)	and	after	6	months	of	daily	 (T6)	probi-
otic supplementation showed a high degree of individual variability in 
miRNA-	29	levels	[coefficient	of	variation	(%):	T0	(miRNA-	29a:	91.30;	
miRNA-	29b:	135.858;	miRNA-	29c:	119.93);	T6	(miRNA-	29a:	118.54;	
miRNA-	29b:	 156.46;	 miRNA-	29c:	 160.32)].	 After	 probiotic	 supple-
mentation,	miRNA-	29a-	c	levels	and	the	pattern	of	miRNA-	29	expres-
sion remained unchanged.
3.4 | Bacterial DNA isolation from fecal samples
We found that fecal Bifidobacteria spp. increased significantly in all 
patients	compared	to	their	basal	level,	after	2	months	of	supplementa-
tion	(p	<	.05)	and	remained	stable	through	the	study	(data	not	shown)	
and this was considered as a proof of compliance to the treatment.
3.5 | Safety of probiotic supplementation
All	patients	received	a	high-	concentration	lyophilized	multistrain	pro-
biotic	powder	supplement	twice	a	day	for	6	months	(1.8	×	109). This 
dosage was well- tolerated throughout the course of the study and 
side effects were not reported.
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4  | DISCUSSION
Neurocognitive disorder affects more than 50% of antiretroviral- 
treated	HIV	 subjects	 (Heaton	 et	al.,	 2010).	 An	 improvement,	 but	
not	 complete	 recovery,	 of	 neurocognitive	 impairment	 has	 been	
reported	in	the	literature,	but	only	after	the	cART	was	intensified	
which often is not a feasible avenue due to the untoward effects 
and	chronic	nature	of	the	disease	(Stilling,	Dinan,	&	Cryan,	2014).	
We	hypothesized	 that	a	new	and	safe	approach	 for	 the	 improve-
ment of the neuropsychological performance of these subjects 
could	be	 the	 administration	of	 probiotics.	 In	 the	 last	 years,	 there	
has	been	an	 increase	 in	experimental	 research,	 conducted	mainly	
on	 animals,	 aimed	 to	 explore	 the	 contribution	 of	 the	 microbiota	
in	 modulating	 gut–brain-	axis	 (GBA).	 The	 discovery	 that	 differen-
tial microbial composition is associated with alterations in behav-
ior and cognition has significantly contributed to establish the 
“microbiota–gut–brain-	axis”	 as	 an	extension	of	 the	well-	accepted	
“gut–brain-	axis”	concept.	This	concept	 is	used	to	describe	the	bi-
directional	communication	between	the	CNS	and	intestinal	organs	
(Gates	et	al.,	2016).
Recent	 studies	 exploring	 the	 effects	 of	 different	 gut	microbiota	
composition on impairment of cognition and behavior have shown 
that	alterations	of	microbioma	composition	are	connected	to	stress,	
modification	of	mood	and	behavior,	worsening	of	cognition	and	that	
probiotics	 can	 play	 a	 protective	 role	 (Carabotti,	 Scirocco,	Maselli,	 &	
Severi,	 2015;	 Jiang	 et	al.,	 2015;	 Steenbergen,	 Sellaro,	 van	 Hemert,	
Bosch,	&	Colzato,	2015).
Since	no	data	were	available,	our	primary	study	end	point	was	to	
verify the safety of a high- concentration multistrain probiotic supple-
mentation at the neurological level. Each patient underwent a lumbar 
puncture before and after probiotic supplementation to verify any 
changes	in	CSF.
All	 HIV-	1-	positive	 patients	 received	 a	 high-	concentration	 lyo-
philized	 multistrain	 probiotic	 powder	 supplement	 twice	 a	 day	 for	
6	months	 (1.8	×	10^9).	 This	 dosage	 was	 well-	tolerated	 throughout	
the course of the study and the potential side effects which had 
been previously reported for other and different formulations were 
not	reported	here	(Anukam,	Osazuwa,	Osadolor,	Bruce,	&	Reid,	2008;	
Haghighat	 &	 Crum-	Cianflone,	 2015;	 Hummelen	 et	al.,	 2011).	 We	
found that fecal Bifidobacteria spp increased in all patients compared 
TABLE  1 Results of neuropsychological test administered before and after 6 months of probiotic supplementation
T0 – median (interquartile range) T6 – median (interquartile range) p value
MMSE	(Mini-	Mental	State	Examination) 30.00	(28.82–30.00) 30.00	(30.00–30.00) .1814
RAVLT	(Rey	Auditory	Verbal	Learning	Test	
Immediate Recall)
46.10	(31.70–47.08) 52.50	(49.35–54.55) .0273
RAVLT	(Rey	Auditory	Verbal	Learning	Test	
Delayed Recall)
7.70	(5.92–10.30) 12.00	(10.38–12.48) .0299
RAVLT	(Rey	Auditory	Verbal	Learning	
Recognition)
95.50	(90.00–99.50) 99.50	(98.00–100.00) .1056
ROCF	(Rey-	Osterrieth	Complex	Figure	Copy	
Immediate recall)
16.30	(15.92–17.03) 21.00	(18.58–22.95) .0058
ROCF	(Rey-	Osterrieth	Complex	Figure	Copy	
Delayed Recall)
15.25	(14.32–16.75) 22.40	(22.00–24.75) .0019
FAB	(Frontal	Assessment	Battery) 14.85	(13.60–15.80) 15.45	(14.21–17.50) .1780
PVF	(Phonological	Verbal	Fluency) 28.50	(22.82–37.88) 43.95	(42.25–44.75) .0137
SVF	(Semantic	Verbal	Fluency) 47.00	(32.75–54.75) 48.50	(45.50–49.00) .3580
TMTA	(Trail	Making	Test	A) 50.00	(44.25–55.00) 46.00	(40.50–54.00) .1395
TMTB	(Trail	Making	Test	B) 117.50	(99.50–122.80) 125.00	(98.50–138.50) .9527
Verbal	Span-	Digit	Forward 4.50	(3.50–5.37) 5.00	(5.00–5.81) .0940
Verbal	Span-	Digit	Back 4.50	(4.00–5.00) 5.00	(4.25–5.00) .5716
Tas-	20	(Toronto	Alexithymia	Scale-	20) 40.00	(35.00–41.00) 50.00	(41.00–54.00) .0421
BDI-	II	(Beck	Depression	Scale	II)
STAY	Y-	1	(State-	Trait	Anxiety	Inventory) 47.00	(45.00–50.00) 55.00	(50.00–70.00) .0751
STAY	Y-	2	(State-	Trait	Anxiety	Inventory) 60.00	(40.00–65.00) 85.00	(65.00–90.00) .0225
AAT	(Aachen	Aphasia	Test) 9.00	(9.00–9.00) 9.00	(9.00–9.00) 1.0000
CBTT-	Forward	(Corsi	block-	tapping	task) 4.37	(4.00–5.00) 5.25	(5.05–5.44) .0322
CBTT-	Backward	(Corsi	block-	tapping	task) 4.00	(3.00–4.00) 4.00	(4.00–4.75) .1198
STEP	Time	(Time	and	Weight	Estimation	test) 16.50	(13.25–22.25) 23.00	(21.25–23.00) .0246
STEP	Weight	(Time	and	Weight	Estimation	test) 19.00	(15.00–19.75) 21.00	(21.00–23.00) .0220
STEP	Total	(Time	and	Weight	Estimation	test) 36.50	(29.75–44.25) 44.50	(43.00–45.00) .0827
Significantly	different	values	are	highlighted	in	bold.
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to	their	basal	level,	at	2	months	of	supplementation	and	remained	sta-
ble throughout the study confirming adherence of the patients to the 
regimen.
Our	results	showed	that	probiotics	do	not	affect	miRNA-	29a-	c	lev-
els	or	the	signature	of	miRNA-	29-	a-	c	in	CSF	collected	from	cART-	fully	
suppressed	HIV-	1-	positive	patients	confirming	the	neurological	safety	
of	the	probiotic	formulation,	a	finding	never	described	before	 in	the	
literature.
Moreover,	 our	 patients	 presented	 a	 relevant	 improvement	 of	
performance in the neuropsychological and behavioral tests after 
6	months	of	probiotic	 intake.	MMSE	was	not	modified	by	6	months	
of	probiotic	supplementation	while	RAVLT	(immediate	and	delayed	re-
call),	ROCF	(immediate	and	delayed	recall),	PVF,	STAY	Y-	2,	and	STEP	
(total,	time	and	weight)	appeared	significantly	improved.
Our data seem to demonstrate that the cognitive domains more in-
volved	are	the	short	and	long	memory	and	the	abstract	reasoning	(one	
of	the	aspects	involved	in	the	executive	functions).	Such	results,	seem	
to	be	aligned	with	what	has	emerged	from	a	previously	study,	in	which	
it has been highlighted that a crucial role in the bidirectional commu-
nication	of	 the	gut–brain-	axis,	 is	covered	by	the	hypothalamic–pitu-
itary	adrenal	(HPA)	axis.	As	well	known,	the	HPA	axis	is	considered	the	
core	 stress	efferent	axis	 that	 coordinates	 the	adaptive	 responses	of	
the	organism	to	stressors	of	any	kind,	and	also	it	is	a	part	of	the	limbic	
system,	a	crucial	zone	of	the	brain	predominantly	involved	in	memory	
and	emotional	responses	(Carabotti	et	al.,	2015;	Gates	et	al.,	2016).
Pending	 the	confirmation	by	 larger	study,	probiotics	supplemen-
tation seems to be a safe dietary approach to improve neurocognitive 
performance	 in	 HIV-	1-	positive	 patients,	 in	 particular	memory	 func-
tions. The same multistrain high- concentration probiotic has been 
shown	to	increase	the	brain-	derived	neurotrophic	factor	(BDNF)	ex-
pression and to attenuate age- related alterations in the hippocampus 
of	rats	(Reitan,	1992).
On	a	pure	speculative	basis,	according	to	what	has	been	observed	
in	animal	models,	probiotics	may	act	on	the	hippocampal	regions	con-
trolling	memory	functions	in	HIV-	positive	subjects	undergoing	antiret-
roviral	treatment	(Mayer	et	al.,	2015),	so	the	manipulation	of	microbial	
taxa	trough	probiotics	may	provide	a	means	by	which	cognition	may	
be altered in a reproducible and consistent manner in order to achieve 
a	beneficial	outcome	for	the	patients	in	all	daily	activities	in	which,	are	
required	cognitive	functions	as	memory	(Lyte	et	al.,	2016).
Significant	variations	have	been	seen	on	the	TAS-	20	that	evaluate	
the	 level	of	alexithymia	and	on	 the	STAY-	Y2	 test,	 that	on	 the	other	
hand,	 in	used	to	measure	the	 level	of	the	anxiety	of	the	patients.	 In	
our	opinion,	based	on	clinical	observation	and	clinical	interviews,	the	
increase of these variables could be due to an increased awareness 
of	the	underlying	disease,	also	reported	by	the	patients	 themselves,	
leading	also	to	the	improvement	of	cognitive	functions.	However,	this	
hypothesis needs further observations.
On	the	basis	of	our	results,	HIV-	positive	patients	treated	with	pro-
biotic supplementation improved their performance significantly in 
some	neurocognitive	domains	 (short	 and	 long	memory	and	abstract	
reasoning),	 while	 their	 abilities	 did	 not	 vary	 in	 the	 other	 domains	
explored.	 At	 this	 moment,	 the	 origin	 of	 this	 clinical	 observation	 is	
unknown.	As	previous	reported,	possible	reason	might	be	due	to	the	
fact that hippocampal regions are involved only in certain aspects of 
neurocognitive	 processes,	 but	 further	 studies	 are	 needed	 to	 under-
stand	this	topic.	Moreover,	we	cannot	rule	out	that	the	power	of	sta-
tistical	 analysis	 has	 been	 reduced	 by	 the	 sample	 size	 of	 the	 cohort	
studied.
This	 study	suffers	 for	 the	 small	 sample	 size	and	 the	 related	sta-
tistical concerns and lacks proper control for multiple correlations. 
However,	the	small	sample	size	 is	 justified	by	the	need	to	verify	the	
safety of this high- concentration multistrain probiotic supplemen-
tation.	 Usually,	 few	 thousand	 million	 probiotic	 bacteria	 have	 been	
administered	 to	AIDS	patients	 and	a	prudent	 approach	 (pilot	 study)	
consequently	was	mandatory.	It	is	evident	that	a	small	sample	size	lim-
its	the	capability	to	analyze	properly	the	results	from	a	statistical	point	
of	view.	However,	 in	 the	 field	of	HIV	many	studies	have	been	pub-
lished even when the number of patients was limited and no control 
group was enrolled as their observations and results prompted larger 
confirmatory	trials.	Moreover,	another	limitation	of	our	study	was	the	
absence	of	a	control	group.	The	reasons	that	explain	the	absence	of	
a control group are essentially related to restrictions indicated by the 
ethics	committee,	namely:	(1)	lumbar	puncture	presents	several	risks	
(i.e.,	seeding	of	infection	to	the	CSF;	epidermoid	tumor	implantation;	
uncal or transtentorial herniation and neurological deterioration; spi-
nal	 hematoma),	 for	 these	 reasons,	 performing	 this	 procedure	 on	 a	
control group of healthy subjects was not considered acceptable by 
the	ethics	committee;	 (2)	 in	addition,	 the	use	of	placebo	 in	HIV	pa-
tients	under	heavy	cART	medication	is	discouraged;,	and	(3)	 last	but	
not	least,	since	the	product	we	administered	is	a	probiotic,	the	placebo	
group should have been on a dietary restriction for all the fermented 
foods	containing	bacterial	species	 (yogurt,	kefir,	sour	cream,	cheese,	
crème	 fraiche,	 salami,	vinegar,	 fish	 sauce,	 etc.).	Unnecessary	dietary	
restrictions	to	HIV-	positive	subjects	are	not	considered	ethically	ac-
ceptable by our Institution.
Furthermore,	although	our	data	suggest	the	improvement	of	some	
cognitive	domains,	we	cannot	 totally	 exclude	 the	possible	 influence	
of the practical effect on neuropsychological performances. The use 
of	parallel/alternate	forms	is	one	possible	approach	to	minimize	prac-
tice	effect,	but	 it	does	not	fully	eliminate	concerns	about	this	 topic.	
Our	findings	seem	to	be	encouraging,	but	future	studies,	carried	out	
with	specific	methodological	procedures,	are	needed	to	support	their	
validity.
In	conclusion,	despite	the	above	limitations	justified	by	the	com-
plexity	of	the	procedures	and	the	ethical	boundaries,	the	findings	of	
this	pilot	study	indicate	that	HIV-	1-	positive	patients	receiving	probi-
otic formulation twice a day for 6 months had significantly improved 
some	 neurological	 cognitive	 functions	 (short	 and	 long	memory	 and	
abstract	 reasoning),	 thus	 supporting	 the	 concept	 that	modifications	
of	the	gut	flora	can	provide	specific	neurological	benefits	in	HIV-	1	pa-
tients in the absence of significant side effects.
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